Table 2 Demographics and clinical characteristics of 68 patients
Characteristics | Total (n = 68) | OED (n = 49) | MED (n = 19) | P value |
|---|---|---|---|---|
Age at diagnosis, year | Â | Â | Â | Â |
   Median | 48 | 45 | 52 | 0.589 |
   Range | 20-83 | 20-73 | 20-83 |  |
Sex | Â | Â | Â | Â |
   Male | 0 | 0 | 0 |  |
   Female | 68 | 49 | 19 |  |
Duration of follow-up, months | Â | Â | Â | Â |
   Median | 41.5 | 46.3 | 34.7 | 0.176 |
   Range | 2.4-186.0 | 2.4-186.0 | 2.5-123.5 |  |
Ann Arbor stage | Â | Â | Â | Â |
   I-II | 45 (66.2%) | 45 (91.8%) | 0 (0%) | <0.001 |
   III-IV | 23 (33.8%) | 4 (8.2%) | 19 (100%) |  |
B symptoms | Â | Â | Â | Â |
   Absent | 63 (92.6%) | 47 (95.9%) | 16 (84.2%) | 0.129 |
   Present | 5 (7.4%) | 2 (4.1%) | 3 (15.8%) |  |
ECOG performance status | Â | Â | Â | Â |
   0-1 | 63 (92.6%) | 47 (95.9%) | 16 (84.2%) | 0.129 |
   2-3 | 5 (7.4%) | 2 (4.1%) | 3 (15.8%) |  |
LDH level | Â | Â | Â | Â |
   Normal | 36 (52.9%) | 29 (59.2%) | 7 (36.8%) | 0.098 |
   Elevated | 26 (38.2%) | 16 (32.7%) | 10 (52.6%) |  |
   Unknown | 6 (8.8%) | 4 (8.1%) | 2 (10.5%) |  |
IPI | Â | Â | Â | Â |
   Low to low-intermediate | 50 (73.5%) | 44 (89.8%) | 6 (31.6%) | <0.001 |
   High-intermediate to high | 16 (23.5%) | 3 (6.1%) | 13 (68.4%) |  |
   Unknown | 2 (2.9%) | 2 (4.1%) | 0 (0%) |  |
Traditional strict criteria | Â | Â | Â | Â |
   Traditional PBL | 43 (63.2%) | 43 (87.8%) | 0 (0%) | N/A |
   Traditional SBL | 25 (36.8%) | 6 (12.2%) | 19 (100%) |  |
Bulky disease | Â | Â | Â | Â |
   No | 66 (97.1%) | 48 (98.0%) | 18 (94.7%) | 0.484 |
   Yes | 2 (2.9%) | 1 (2.0%) | 1 (5.3%) |  |
Systemic chemotherapy | Â | Â | Â | Â |
   No | 1 (1.5%) | 0 (0%) | 1 (5.3%) | 0.279 |
   Yes | 67 (98.5%) | 49 (100%) | 18 (94.7%) |  |
Surgery of the breast | Â | Â | Â | Â |
   No | 45 (66.2%) | 28 (57.1%) | 17 (89.5%) | 0.012 |
   Yes | 23 (33.8%) | 21 (42.9%) | 2 (10.5%) |  |
Radiotherapy to the breast | Â | Â | Â | Â |
   No | 47 (69.1%) | 29 (59.2%) | 18 (94.7%) | 0.004 |
   Yes | 21 (30.9%) | 20 (40.8%) | 1 (5.3%) |  |
Treatment strategy | Â | Â | Â | Â |
   <4 cycles ± local modalities | 12 (17.6%) | 8 (16.3%) | 4 (21.1%) | 0.577 |
   ≥4 cycles ± local modalities | 55 (80.9%) | 41 (83.7%) | 14 (73.6%) |  |
   No treatment | 1 (1.5%) | 0 (0%) | 1 (5.3%) |  |
Rituximab use | Â | Â | Â | Â |
   No | 26 (38.2%) | 23 (46.9%) | 3 (15.8%) | 0.025 |
   Yes | 42 (61.8%) | 26 (53.1%) | 16 (84.2%) |  |
Enroll period | Â | Â | Â | Â |
   1994-2002 | 21 (30.9%) | 19 (38.8%) | 2 (10.5%) | 0.039 |
   2003-2009 | 47 (69.1%) | 30 (61.2%) | 17 (89.5%) |  |
Extranodal involvement | Â | Â | Â | Â |
   Breast | 68 (100%) | 49 (100%) | 19 (100%) | N/A |
   Liver | 6 (8.8%) | 0 | 6 (31.6%) |  |
   Bone | 6 (8.8%) | 0 | 6 (31.6%) |  |
   Lung | 4 (5.9%) | 0 | 4 (21.1%) |  |
   Bone marrow | 4 (5.9%) | 0 | 4 (21.1%) |  |
   Stomach | 3 (4.4%) | 0 | 3 (15.8%) |  |
   Nasal cavity | 3 (4.4%) | 0 | 3 (15.8%) |  |
   Central nervous system | 3 (4.4%) | 0 | 3 (15.8%) |  |
   Adrenal gland | 2 (2.9%) | 0 | 2 (10.5%) |  |
   Pancreas | 2 (2.9%) | 0 | 2 (10.5%) |  |
   Thyroid | 1 (1.5%) | 0 | 1 (5.3%) |  |
   Ovary | 1 (1.5%) | 0 | 1 (5.3%) |  |